Kenya vs Pakistan: Average cost of drugs for extensively drug-resistant tuberculosis
Kenya
1,800 constant 2022 US$
in 2024
Pakistan
1,923 constant 2022 US$
in 2024
Kenya rank
29th
Pakistan rank
27th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Kenya
- Pakistan
How they compare
Pakistan currently reports 1,923 constant 2022 US$ against 1,800 constant 2022 US$ in Kenya, a difference of 123 constant 2022 US$.
That makes Pakistan's figure about 1.1 times Kenya's.
The two have swapped places 4 times across 8 shared years of data; in 2017 it was Pakistan ahead.
Kenya ranks 29th and Pakistan ranks 27th of 56 countries.
Pakistan has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Kenya | Pakistan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 4,500 constant 2022 US$ | 8,635 constant 2022 US$ | 4,135 constant 2022 US$ | Pakistan |
| 2020s | 2,706 constant 2022 US$ | 2,824 constant 2022 US$ | 117.6 constant 2022 US$ | Pakistan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Kenya or Pakistan?
- Pakistan, at 1,923 constant 2022 US$ against 1,800 constant 2022 US$ in Kenya as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Kenya and Pakistan?
- 123 constant 2022 US$, with Pakistan ahead.
- How many years of comparable data are there for Kenya and Pakistan?
- 8 years are reported by both, from 2017 to 2024.
- How do Kenya and Pakistan rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Kenya ranks 29th and Pakistan ranks 27th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.